WilmerHale Represents Infinity Pharmaceuticals in $92M Public Offering

WilmerHale Represents Infinity Pharmaceuticals in $92M Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company, in connection with its underwritten public offering of 24,150,000 shares of common stock, including the full exercise of the underwriters’ option to purchase 3,150,000 shares of common stock, at a public offering price of $3.80 per share. The gross proceeds to Infinity were approximately $91.8 million, before deducting underwriting discounts and offering expenses. The offering priced on February 12, 2021 and closed on February 17, 2021.

The WilmerHale team representing Infinity was led by Cynthia Mazareas, and included Stephanie Leopold, Jason Hyatt, Taylor Gibson, Meghan Muncey and Elijah Soko.

For more information, read Infinity’s press release.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel